SMN1 and proximal spinal muscular atrophy: Small molecule HDAC inhibitors like 4PBA36, VX-56336 and AR42 (this study) offer another SMN-independent protective strategy that could be used in concert with SMN2 inducers to maximize therapeutic outcomes in SMA patients.